首页 > 最新文献

Medical Gas Research最新文献

英文 中文
Anesthetic gas consumption with target-controlled administration versus a semi-closed circle system with automatic end-tidal concentration control in an artificial lung model 人工肺模型中目标控制给药的麻醉气体消耗与自动潮气末浓度控制的半闭环系统
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-17 DOI: 10.4103/2045-9912.337991
M. Bellgardt, V. Vinnikov, A. Georgevici, Livia Procopiuc, T. Weber, A. Meiser, J. Herzog-Niescery, D. Drees
The use of volatile anesthetics as sedatives in the intensive care unit is relevant to the patient's outcome. We compared anesthetic gas consumption of the conventional semi-closed Aisys CS™ with the MIRUS™ system, which is the first anesthetic gas reflector system that can administer desflurane in addition to isoflurane and sevoflurane. We connected an artificial lung model to either a MIRUS™ system and a Puritan Bennett™ 840 ventilator or an Aisys CS™ anesthesia machine. We found that consumption of 0.5% isoflurane, which corresponds to the target concentration 0.5 MAC, was averaged to 2 mL/h in the MIRUS™ system, which is identical to the Aisys CS™ at a fresh gas flow (FGF) of 1.0 L/min. MIRUS™ consumption of 1% sevoflurane was averaged to 10 mL/h, which corresponds to 8.4 mL/h at FGF 2.5 L/min. The MIRUS™ system consumed 3% or 4% desflurane at an average of 13.0 mL/h or 21.3 mL/h, which is between the consumption at 1.0 L/min and 2.5 L/min FGF. Thus, the MIRUS™ system can effectively deliver volatile anesthetics in clinically relevant concentrations in a similar rate as a conventional circular breathing system at FGFs between 1.0 L/min and 2.5 L/min.
在重症监护室使用挥发性麻醉剂作为镇静剂与患者的预后有关。我们比较了传统的半封闭Aisys CS的麻醉气体消耗™ 与MIRUS™ 该系统是第一个除异氟烷和七氟醚外还可以使用地氟醚的麻醉气体反射系统。我们将人工肺模型连接到MIRU™ 制度与清教徒Bennett™ 840呼吸机或Aisys CS™ 麻醉机。我们发现,在MIRUS中,0.5%异氟烷的消耗量(相当于目标浓度0.5MAC)平均为2mL/h™ 系统,与Aisys CS相同™ 新鲜气体流量(FGF)为1.0L/min。米鲁斯™ 1%七氟醚的消耗量平均为10mL/h,相当于FGF为2.5L/min时的8.4mL/h。MIRUS™ 系统以13.0 mL/h或21.3 mL/h的平均消耗量消耗3%或4%的地氟醚,介于1.0 L/min和2.5 L/min FGF的消耗量之间。因此,MIRUS™ 该系统可以在1.0L/min和2.5L/min之间的FGF下以与传统循环呼吸系统相似的速率有效地递送临床相关浓度的挥发性麻醉剂。
{"title":"Anesthetic gas consumption with target-controlled administration versus a semi-closed circle system with automatic end-tidal concentration control in an artificial lung model","authors":"M. Bellgardt, V. Vinnikov, A. Georgevici, Livia Procopiuc, T. Weber, A. Meiser, J. Herzog-Niescery, D. Drees","doi":"10.4103/2045-9912.337991","DOIUrl":"https://doi.org/10.4103/2045-9912.337991","url":null,"abstract":"The use of volatile anesthetics as sedatives in the intensive care unit is relevant to the patient's outcome. We compared anesthetic gas consumption of the conventional semi-closed Aisys CS™ with the MIRUS™ system, which is the first anesthetic gas reflector system that can administer desflurane in addition to isoflurane and sevoflurane. We connected an artificial lung model to either a MIRUS™ system and a Puritan Bennett™ 840 ventilator or an Aisys CS™ anesthesia machine. We found that consumption of 0.5% isoflurane, which corresponds to the target concentration 0.5 MAC, was averaged to 2 mL/h in the MIRUS™ system, which is identical to the Aisys CS™ at a fresh gas flow (FGF) of 1.0 L/min. MIRUS™ consumption of 1% sevoflurane was averaged to 10 mL/h, which corresponds to 8.4 mL/h at FGF 2.5 L/min. The MIRUS™ system consumed 3% or 4% desflurane at an average of 13.0 mL/h or 21.3 mL/h, which is between the consumption at 1.0 L/min and 2.5 L/min FGF. Thus, the MIRUS™ system can effectively deliver volatile anesthetics in clinically relevant concentrations in a similar rate as a conventional circular breathing system at FGFs between 1.0 L/min and 2.5 L/min.","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 1","pages":"131 - 136"},"PeriodicalIF":2.9,"publicationDate":"2022-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46610360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Looking for more than hot air: how experimental design can enhance clinical evidence for hyperbaric oxygen therapy 寻找的不仅仅是热空气:实验设计如何增强高压氧治疗的临床证据
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-17 DOI: 10.4103/2045-9912.337992
Adam T. Biggs, Lanny F. Littlejohn
Hyperbaric oxygen therapy is emerging as a potential treatment for critical medical and psychological issues, including mild traumatic brain injury, traumatic brain injury, and post-traumatic stress disorder. Based on the promising results from numerous case studies, randomized clinical trials generated conflicting interpretations despite frequent improvements in patient symptoms. The primary debate concerns whether the therapeutic benefits could be attributed to placebo effects or sham conditions that actually induce a therapeutic state. In part, the contention has been exacerbated by experimental designs which could not properly account for extraneous variables, such as the potential for differing patient expectations to influence the outcome. The current discussion addresses five methodological challenges that complicate any determination of clinical significance due to experimental design. These challenges include: 1) not properly addressing or controlling patient expectations prior to the experimental sessions; 2) the challenge of experimental masking in clinical designs that require pressurized environments; 3) patient subjectivity in the primary dependent variables; 4) potential fluidity in patient symptoms or data, such as regression to the mean; and 5) the potential for nocebo effects to exaggerate treatment benefits by lowering performance expectations during pre-treatment assessments. Each factor provides an influential means by which placebo effects could complicate results and prevent the combined data from reaching a threshold of clinical significance. The discussion concludes with methodological best practices with which future research could minimize placebo effects and produce more conclusive results.
高压氧治疗正在成为一种潜在的治疗关键医疗和心理问题的方法,包括轻度创伤性脑损伤、创伤性脑损伤和创伤后应激障碍。基于大量病例研究的有希望的结果,尽管患者症状经常得到改善,但随机临床试验产生了相互矛盾的解释。主要的争论是,治疗益处是否可以归因于安慰剂效应或实际诱导治疗状态的虚假条件。在某种程度上,实验设计无法正确解释无关变量,例如患者期望值不同可能影响结果,这加剧了争论。目前的讨论涉及五个方法学挑战,这些挑战使实验设计导致的临床意义的确定变得复杂。这些挑战包括:1)在实验前没有正确解决或控制患者的期望;2) 在需要加压环境的临床设计中进行实验掩蔽的挑战;3) 患者主体性在主要因变量中;4) 患者症状或数据的潜在流动性,如回归到平均值;以及5)nocebo效应可能通过降低治疗前评估期间的表现预期来夸大治疗效果。每一个因素都提供了一种有影响力的手段,安慰剂效应可能会使结果复杂化,并阻止组合数据达到临床意义的阈值。讨论以方法论最佳实践结束,未来的研究可以最大限度地减少安慰剂效应,并产生更具结论性的结果。
{"title":"Looking for more than hot air: how experimental design can enhance clinical evidence for hyperbaric oxygen therapy","authors":"Adam T. Biggs, Lanny F. Littlejohn","doi":"10.4103/2045-9912.337992","DOIUrl":"https://doi.org/10.4103/2045-9912.337992","url":null,"abstract":"Hyperbaric oxygen therapy is emerging as a potential treatment for critical medical and psychological issues, including mild traumatic brain injury, traumatic brain injury, and post-traumatic stress disorder. Based on the promising results from numerous case studies, randomized clinical trials generated conflicting interpretations despite frequent improvements in patient symptoms. The primary debate concerns whether the therapeutic benefits could be attributed to placebo effects or sham conditions that actually induce a therapeutic state. In part, the contention has been exacerbated by experimental designs which could not properly account for extraneous variables, such as the potential for differing patient expectations to influence the outcome. The current discussion addresses five methodological challenges that complicate any determination of clinical significance due to experimental design. These challenges include: 1) not properly addressing or controlling patient expectations prior to the experimental sessions; 2) the challenge of experimental masking in clinical designs that require pressurized environments; 3) patient subjectivity in the primary dependent variables; 4) potential fluidity in patient symptoms or data, such as regression to the mean; and 5) the potential for nocebo effects to exaggerate treatment benefits by lowering performance expectations during pre-treatment assessments. Each factor provides an influential means by which placebo effects could complicate results and prevent the combined data from reaching a threshold of clinical significance. The discussion concludes with methodological best practices with which future research could minimize placebo effects and produce more conclusive results.","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 1","pages":"116 - 124"},"PeriodicalIF":2.9,"publicationDate":"2022-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42649456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Perioperative melatonin in COVID-19 patients: benefits beyond sedation and analgesia. COVID-19患者围手术期褪黑素:镇静和镇痛以外的益处
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-01 DOI: 10.4103/2045-9912.325990
Abhijit S Nair

Cytokine storm in coronavirus disease 2019 (COVID-19) patients leads to acute lung injury, acute respiratory distress syndrome, multiorgan dysfunction, shock, and thrombosis thus contributing to significant morbidity and mortality. Several agents like steroids, ascorbic acid, vitamins (C, D, E), glutathione, N-acetylcysteine have been used and several studies are underway to identify its efficacy in addressing undesirable effects due to COVID-19 illness. Among several experimental modalities based on expert opinion and anecdotal data, melatonin is one molecule that appears promising. Owing to its anti-inflammatory, anti-oxidant, and immunomodulatory properties, melatonin can be an important agent used as a component of multimodal analgesia in COVID-19 patients, suspected patients, and patients with exposure to positive patients undergoing emergency or urgent surgeries. Further research is required to know the optimal time of initiation, dose, and duration of melatonin as an adjunct.

2019冠状病毒病(COVID-19)患者的细胞因子风暴可导致急性肺损伤、急性呼吸窘迫综合征、多器官功能障碍、休克和血栓形成,从而导致显著的发病率和死亡率。已经使用了类固醇、抗坏血酸、维生素(C、D、E)、谷胱甘肽、n -乙酰半胱氨酸等几种药物,目前正在进行几项研究,以确定其在解决COVID-19疾病引起的不良影响方面的功效。在基于专家意见和轶事数据的几种实验模式中,褪黑素是一种看起来很有希望的分子。由于其抗炎、抗氧化和免疫调节特性,褪黑素可作为COVID-19患者、疑似患者和接触阳性患者进行急诊或紧急手术的患者的多模式镇痛的重要组成部分。需要进一步的研究来了解褪黑素作为辅助药物的最佳起始时间、剂量和持续时间。
{"title":"Perioperative melatonin in COVID-19 patients: benefits beyond sedation and analgesia.","authors":"Abhijit S Nair","doi":"10.4103/2045-9912.325990","DOIUrl":"https://doi.org/10.4103/2045-9912.325990","url":null,"abstract":"<p><p>Cytokine storm in coronavirus disease 2019 (COVID-19) patients leads to acute lung injury, acute respiratory distress syndrome, multiorgan dysfunction, shock, and thrombosis thus contributing to significant morbidity and mortality. Several agents like steroids, ascorbic acid, vitamins (C, D, E), glutathione, N-acetylcysteine have been used and several studies are underway to identify its efficacy in addressing undesirable effects due to COVID-19 illness. Among several experimental modalities based on expert opinion and anecdotal data, melatonin is one molecule that appears promising. Owing to its anti-inflammatory, anti-oxidant, and immunomodulatory properties, melatonin can be an important agent used as a component of multimodal analgesia in COVID-19 patients, suspected patients, and patients with exposure to positive patients undergoing emergency or urgent surgeries. Further research is required to know the optimal time of initiation, dose, and duration of melatonin as an adjunct.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 2","pages":"41-43"},"PeriodicalIF":2.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/98/MGR-12-41.PMC8562396.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Prediction of diagnosis and prognosis of COVID-19 disease by blood gas parameters using decision trees machine learning model: a retrospective observational study. 基于决策树机器学习模型的血气参数预测COVID-19疾病诊断和预后的回顾性观察研究
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-01 DOI: 10.4103/2045-9912.326002
Mehmet Tahir Huyut, Hilal Üstündağ

The coronavirus disease 2019 (COVID-19) epidemic went down in history as a pandemic caused by corona-viruses that emerged in 2019 and spread rapidly around the world. The different symptoms of COVID-19 made it difficult to understand which variables were more influential on the diagnosis, course and mortality of the disease. Machine learning models can accurately assess hidden patterns among risk factors by analyzing large-datasets to quickly predict diagnosis, prognosis and mortality of diseases. Because of this advantage, the use of machine learning models as decision support systems in health services is increasing. The aim of this study is to determine the diagnosis and prognosis of COVID-19 disease with blood-gas data using the Chi-squared Automatic Interaction Detector (CHAID) decision-tree-model, one of the machine learning methods, which is a subfield of artificial intelligence. This study was carried out on a total of 686 patients with COVID-19 (n = 343) and non-COVID-19 (n = 343) treated at Erzincan-Mengücek-Gazi-Training and Research-Hospital between April 1, 2020 and March 1, 2021. Arterial blood gas values of all patients were obtained from the hospital registry system. While the total-accuracyratio of the decision-tree-model was 65.0% in predicting the prognosis of the disease, it was 68.2% in the diagnosis of the disease. According to the results obtained, the low ionized-calcium value (< 1.10 mM) significantly predicted the need for intensive care of COVID-19 patients. At admission, low-carboxyhemoglobin (< 1.00%), high-pH (> 7.43), low-sodium (< 135.0 mM), hematocrit (< 40.0%), and methemoglobin (< 1.30%) values are important biomarkers in the diagnosis of COVID-19 and the results were promising. The findings in the study may aid in the early-diagnosis of the disease and the intensive-care treatment of patients who are severe. The study was approved by the Ministry of Health and Erzincan University Faculty of Medicine Clinical Research Ethics Committee.

2019冠状病毒病(COVID-19)疫情作为2019年出现并在全球迅速蔓延的冠状病毒引起的大流行而载入史册。COVID-19的不同症状使得很难理解哪些变量对疾病的诊断、病程和死亡率的影响更大。机器学习模型可以通过分析大数据集,准确评估风险因素之间的隐藏模式,快速预测疾病的诊断、预后和死亡率。由于这一优势,在卫生服务中越来越多地使用机器学习模型作为决策支持系统。本研究的目的是利用机器学习方法之一的卡方自动交互检测器(CHAID)决策树模型,利用血气数据确定COVID-19疾病的诊断和预后,这是人工智能的一个分支。本研究对2020年4月1日至2021年3月1日期间在erzincan - meng cek- gazi培训和研究医院治疗的686例COVID-19患者(n = 343)和非COVID-19患者(n = 343)进行了研究。所有患者的动脉血气值均从医院登记系统获取。决策树模型预测疾病预后的总准确率为65.0%,诊断疾病的总准确率为68.2%。结果显示,低离子钙值(< 1.10 mM)可显著预测COVID-19患者是否需要重症监护。入院时,低碳氧血红蛋白(< 1.00%)、高ph(> 7.43)、低钠(< 135.0 mM)、红细胞压积(< 40.0%)和高铁血红蛋白(< 1.30%)值是诊断COVID-19的重要生物标志物,结果令人期待。研究结果可能有助于疾病的早期诊断和重症患者的重症监护治疗。本研究经卫生部和额尔津詹大学医学院临床研究伦理委员会批准。
{"title":"Prediction of diagnosis and prognosis of COVID-19 disease by blood gas parameters using decision trees machine learning model: a retrospective observational study.","authors":"Mehmet Tahir Huyut,&nbsp;Hilal Üstündağ","doi":"10.4103/2045-9912.326002","DOIUrl":"https://doi.org/10.4103/2045-9912.326002","url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) epidemic went down in history as a pandemic caused by corona-viruses that emerged in 2019 and spread rapidly around the world. The different symptoms of COVID-19 made it difficult to understand which variables were more influential on the diagnosis, course and mortality of the disease. Machine learning models can accurately assess hidden patterns among risk factors by analyzing large-datasets to quickly predict diagnosis, prognosis and mortality of diseases. Because of this advantage, the use of machine learning models as decision support systems in health services is increasing. The aim of this study is to determine the diagnosis and prognosis of COVID-19 disease with blood-gas data using the Chi-squared Automatic Interaction Detector (CHAID) decision-tree-model, one of the machine learning methods, which is a subfield of artificial intelligence. This study was carried out on a total of 686 patients with COVID-19 (n = 343) and non-COVID-19 (n = 343) treated at Erzincan-Mengücek-Gazi-Training and Research-Hospital between April 1, 2020 and March 1, 2021. Arterial blood gas values of all patients were obtained from the hospital registry system. While the total-accuracyratio of the decision-tree-model was 65.0% in predicting the prognosis of the disease, it was 68.2% in the diagnosis of the disease. According to the results obtained, the low ionized-calcium value (< 1.10 mM) significantly predicted the need for intensive care of COVID-19 patients. At admission, low-carboxyhemoglobin (< 1.00%), high-pH (> 7.43), low-sodium (< 135.0 mM), hematocrit (< 40.0%), and methemoglobin (< 1.30%) values are important biomarkers in the diagnosis of COVID-19 and the results were promising. The findings in the study may aid in the early-diagnosis of the disease and the intensive-care treatment of patients who are severe. The study was approved by the Ministry of Health and Erzincan University Faculty of Medicine Clinical Research Ethics Committee.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 2","pages":"60-66"},"PeriodicalIF":2.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/cd/MGR-12-60.PMC8562394.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39542732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 29
Potential therapeutic effect of oxygen-ozone in controlling of COVID-19 disease. 氧臭氧在控制COVID-19疾病中的潜在治疗效果。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-01 DOI: 10.4103/2045-9912.325989
Bahman Yousefi, Seyedeh Zahra Banihashemian, Zahra Khatibiyan Feyzabadi, Sahar Hasanpour, Parviz Kokhaei, Anna Abdolshahi, Alireza Emadi, Majid Eslami

Atmospheric ozone is produced when nitrogen oxides react with volatile organic compounds. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome contains a unique N-terminal fragment in the Spike protein, which allows it to bind to air pollutants in the environment. 'Our approach in this review is to study ozone and its effect on the SARS-CoV-2 virus and patients with coronavirus disease 2019 (COVID-19). Article data were collected from PubMed, Scopus, and Google Scholar databases. Ozone therapy has antiviral properties, improves blood flow, facilitates the transfer of oxygen in hypoxemic tissues, and reduces blood coagulation phenomena in COVID-19 patients. Ozone has immunomodulatory effects by modulating cytokines (reduction of interleukin-1, interleukin-6, tumor necrosis factor-α, and interleukin-10), induction of interferon-γ, anti-inflammatory properties by modulating NOD-, LRR- and pyrin domain-containing protein 3, inhibition of cytokine storm (blocking nuclear factor-κB and stimulating nuclear factor erythroid 2-related factor 2 pathway), stimulates cellular/humoral immunity/phagocytic function and blocks angiotensin-converting enzyme 2. In direct oxygen-ozone injection, oxygen reacts with several biological molecules such as thiol groups in albumin to form ozonoids. Intravenous injection of ozonated saline significantly increases the length of time a person can remain hypoxic. The rectal ozone protocol is rectal ozone insufflation, resulting in clinical improvement in oxygen saturation and biochemical improvement (fibrinogen, D-dimer, urea, ferritin, LDH, interleukin-6, and C-reactive protein). In general, many studies have shown the positive effect of ozone therapy as a complementary therapy in the recovery of COVID-19 patients. All the findings indicate that systemic ozone therapy is nontoxic and has no side effects in these patients.

大气中的臭氧是由氮氧化物与挥发性有机化合物反应产生的。严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)基因组在刺突蛋白中含有一个独特的N端片段,使其能够与环境中的空气污染物结合我们在这篇综述中的方法是研究臭氧及其对SARS-CoV-2病毒和2019冠状病毒病(新冠肺炎)患者的影响。文章数据来自PubMed、Scopus和Google Scholar数据库。臭氧疗法具有抗病毒特性,改善血液流动,促进低氧组织中氧气的转移,并减少新冠肺炎患者的凝血现象。臭氧通过调节细胞因子(减少白细胞介素-1、白细胞介素-6、肿瘤坏死因子-α和白细胞介质-10)具有免疫调节作用,诱导干扰素-γ,通过调节含NOD-、LRR-和pyrin结构域的蛋白3具有抗炎特性,抑制细胞因子风暴(阻断核因子-κB和刺激核因子-红系2相关因子2途径),刺激细胞/体液免疫/吞噬功能并阻断血管紧张素转化酶2。在直接氧气-臭氧注射中,氧气与白蛋白中的巯基等几种生物分子反应形成臭氧化合物。静脉注射臭氧盐水显著增加了一个人缺氧的时间长度。直肠臭氧方案是直肠臭氧吹入,导致血氧饱和度的临床改善和生化改善(纤维蛋白原、D-二聚体、尿素、铁蛋白、LDH、白细胞介素-6和C反应蛋白)。总体而言,许多研究表明臭氧疗法作为补充疗法对新冠肺炎患者的康复具有积极作用。所有研究结果表明,全身臭氧治疗对这些患者无毒且无副作用。
{"title":"Potential therapeutic effect of oxygen-ozone in controlling of COVID-19 disease.","authors":"Bahman Yousefi,&nbsp;Seyedeh Zahra Banihashemian,&nbsp;Zahra Khatibiyan Feyzabadi,&nbsp;Sahar Hasanpour,&nbsp;Parviz Kokhaei,&nbsp;Anna Abdolshahi,&nbsp;Alireza Emadi,&nbsp;Majid Eslami","doi":"10.4103/2045-9912.325989","DOIUrl":"10.4103/2045-9912.325989","url":null,"abstract":"<p><p>Atmospheric ozone is produced when nitrogen oxides react with volatile organic compounds. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome contains a unique N-terminal fragment in the Spike protein, which allows it to bind to air pollutants in the environment. 'Our approach in this review is to study ozone and its effect on the SARS-CoV-2 virus and patients with coronavirus disease 2019 (COVID-19). Article data were collected from PubMed, Scopus, and Google Scholar databases. Ozone therapy has antiviral properties, improves blood flow, facilitates the transfer of oxygen in hypoxemic tissues, and reduces blood coagulation phenomena in COVID-19 patients. Ozone has immunomodulatory effects by modulating cytokines (reduction of interleukin-1, interleukin-6, tumor necrosis factor-α, and interleukin-10), induction of interferon-γ, anti-inflammatory properties by modulating NOD-, LRR- and pyrin domain-containing protein 3, inhibition of cytokine storm (blocking nuclear factor-κB and stimulating nuclear factor erythroid 2-related factor 2 pathway), stimulates cellular/humoral immunity/phagocytic function and blocks angiotensin-converting enzyme 2. In direct oxygen-ozone injection, oxygen reacts with several biological molecules such as thiol groups in albumin to form ozonoids. Intravenous injection of ozonated saline significantly increases the length of time a person can remain hypoxic. The rectal ozone protocol is rectal ozone insufflation, resulting in clinical improvement in oxygen saturation and biochemical improvement (fibrinogen, D-dimer, urea, ferritin, LDH, interleukin-6, and C-reactive protein). In general, many studies have shown the positive effect of ozone therapy as a complementary therapy in the recovery of COVID-19 patients. All the findings indicate that systemic ozone therapy is nontoxic and has no side effects in these patients.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 2","pages":"33-40"},"PeriodicalIF":2.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/63/MGR-12-33.PMC8562402.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Effects of Iranian Polyherbal Syrup (Zufa syrup) on oxygen saturation and clinical symptoms in suspected patients with COVID-19: a triple-blinded, randomized, placebo-controlled trial. 伊朗多草药糖浆对疑似COVID-19患者血氧饱和度和临床症状的影响:一项三盲、随机、安慰剂对照试验
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-01 DOI: 10.4103/2045-9912.325991
Razieh Borujerdi, Seyed Hasan Adeli, Abolfazl Mohammadbeigi, Fatemeh Aliasl, Akram Asghari, Ahmad Hormati, Hosein Moradi Dehnavi, Farhad Hoseini, Majid Asghari

Coronavirus disease 2019 (COVID-19) pandemic has caused an urgent need for investigating potential treatments. Traditional medicine offers many potential remedies that have been historically used and have the advantage of bypassing the cultural obstacles in the practice of medicine. We aimed to investigate the efficacy of Zufa syrup in the treatment of suspected patients with mild to moderate symptoms of COVID-19. This triple-blind randomized controlled trial recruited patients with evidence of COVID-19 on chest computed tomography without an indication of hospital admission from March 2020 until April 2020. Participants were assessed by a physician and completed a pre-specified form to assess the duration and severity of symptoms. Patients were randomized to receive Zufa syrup (a combination of herbal medicines: Nepetabracteata, Ziziphus jujube, Glycyrrhizaglabra, Ficuscarica, Cordia myxa, Papaver somniferum, Fennel, Adiantumcapillus-veneris, Viola, Viper's-buglosses, Lavender, Iris, and sugar) or identical-looking placebo syrup at a dose of 7.5 mL (one tablespoon) every 4 hours for 10 days. After applying the eligibility criteria, 116 patients (49.1% male) were randomized to trial arms with a mean age of 44.3. During the follow-up, Cough, dyspnea, headache, myalgia, anorexia, anxiety, and insomnia improved gradually in both groups, and showed no difference between Zufa syrup and placebo. Oxygen saturation and pulse rate had stable trends throughout the follow-up and were similar between study arms. No patient required hospital admission or supplemental oxygen therapy during the study period. To conclude, in patients with mild to moderate symptoms of COVID-19, Zufa syrup did not show any difference in symptomatology over a 10 days' period when compared with placebo. Due to potential effects of medicinal plants in the treatment of respiratory infections, further studies are warranted to clarify their role in COVID-19. The study was approved by the Ethics Committee of the Qom University of Medical Science (Ethics committee reference number IR.MUQ.REC.1398.165) on March 10, 2020 and was registered in Iranian Clinical Trial Center (approval ID: IRCT20200404046934N1) on April 13, 2020.

2019冠状病毒病(COVID-19)大流行导致迫切需要研究潜在的治疗方法。传统医学提供了许多潜在的治疗方法,这些方法在历史上被使用过,并且在医学实践中具有绕过文化障碍的优势。我们旨在探讨祖法糖浆治疗新冠肺炎轻中度疑似患者的疗效。这项三盲随机对照试验招募了2020年3月至2020年4月期间在胸部计算机断层扫描上有COVID-19证据且没有住院迹象的患者。由医生对参与者进行评估,并完成预先指定的表格,以评估症状的持续时间和严重程度。患者随机接受Zufa糖浆(草药的组合:Nepetabracteata, Ziziphus枣,Glycyrrhizaglabra, Ficuscarica, Cordia myxa, Papaver somniferum,茴香,adiantumcapillus veneris, Viola, Viper's- bugless,薰衣草,鸢尾花和糖)或相同外观的安慰剂糖浆,剂量为每4小时7.5 mL(一汤匙),持续10天。应用资格标准后,116例患者(49.1%为男性)被随机分配到平均年龄为44.3岁的试验组。随访期间,两组患者咳嗽、呼吸困难、头痛、肌痛、厌食、焦虑、失眠等症状均逐渐改善,祖发糖浆与安慰剂无显著差异。在整个随访过程中,血氧饱和度和脉搏率有稳定的趋势,各研究组之间的趋势相似。在研究期间,没有患者需要住院或补充氧气治疗。总之,在患有轻至中度COVID-19症状的患者中,与安慰剂相比,祖法糖浆在10天内没有表现出任何症状差异。由于药用植物在治疗呼吸道感染方面的潜在作用,需要进一步研究以阐明其在COVID-19中的作用。本研究已于2020年3月10日获得库姆医科大学伦理委员会批准(伦理委员会参考号IR.MUQ.REC.1398.165),并于2020年4月13日在伊朗临床试验中心注册(批准号:IRCT20200404046934N1)。
{"title":"Effects of Iranian Polyherbal Syrup (Zufa syrup) on oxygen saturation and clinical symptoms in suspected patients with COVID-19: a triple-blinded, randomized, placebo-controlled trial.","authors":"Razieh Borujerdi,&nbsp;Seyed Hasan Adeli,&nbsp;Abolfazl Mohammadbeigi,&nbsp;Fatemeh Aliasl,&nbsp;Akram Asghari,&nbsp;Ahmad Hormati,&nbsp;Hosein Moradi Dehnavi,&nbsp;Farhad Hoseini,&nbsp;Majid Asghari","doi":"10.4103/2045-9912.325991","DOIUrl":"https://doi.org/10.4103/2045-9912.325991","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) pandemic has caused an urgent need for investigating potential treatments. Traditional medicine offers many potential remedies that have been historically used and have the advantage of bypassing the cultural obstacles in the practice of medicine. We aimed to investigate the efficacy of Zufa syrup in the treatment of suspected patients with mild to moderate symptoms of COVID-19. This triple-blind randomized controlled trial recruited patients with evidence of COVID-19 on chest computed tomography without an indication of hospital admission from March 2020 until April 2020. Participants were assessed by a physician and completed a pre-specified form to assess the duration and severity of symptoms. Patients were randomized to receive Zufa syrup (a combination of herbal medicines: Nepetabracteata, Ziziphus jujube, Glycyrrhizaglabra, Ficuscarica, Cordia myxa, Papaver somniferum, Fennel, Adiantumcapillus-veneris, Viola, Viper's-buglosses, Lavender, Iris, and sugar) or identical-looking placebo syrup at a dose of 7.5 mL (one tablespoon) every 4 hours for 10 days. After applying the eligibility criteria, 116 patients (49.1% male) were randomized to trial arms with a mean age of 44.3. During the follow-up, Cough, dyspnea, headache, myalgia, anorexia, anxiety, and insomnia improved gradually in both groups, and showed no difference between Zufa syrup and placebo. Oxygen saturation and pulse rate had stable trends throughout the follow-up and were similar between study arms. No patient required hospital admission or supplemental oxygen therapy during the study period. To conclude, in patients with mild to moderate symptoms of COVID-19, Zufa syrup did not show any difference in symptomatology over a 10 days' period when compared with placebo. Due to potential effects of medicinal plants in the treatment of respiratory infections, further studies are warranted to clarify their role in COVID-19. The study was approved by the Ethics Committee of the Qom University of Medical Science (Ethics committee reference number IR.MUQ.REC.1398.165) on March 10, 2020 and was registered in Iranian Clinical Trial Center (approval ID: IRCT20200404046934N1) on April 13, 2020.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 2","pages":"44-50"},"PeriodicalIF":2.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/cb/MGR-12-44.PMC8562395.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39542730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Can united airway disease be the cause of variable severity experience of COVID-19 in health care workers? 联合气道疾病会导致卫生保健工作者出现不同程度的COVID-19感染吗?
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-01 DOI: 10.4103/2045-9912.326004
Merih Onal, Ozkan Onal, Alparslan Turan
{"title":"Can united airway disease be the cause of variable severity experience of COVID-19 in health care workers?","authors":"Merih Onal,&nbsp;Ozkan Onal,&nbsp;Alparslan Turan","doi":"10.4103/2045-9912.326004","DOIUrl":"https://doi.org/10.4103/2045-9912.326004","url":null,"abstract":"","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 2","pages":"69-71"},"PeriodicalIF":2.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/20/MGR-12-69.PMC8562400.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39542734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial. 雾化应用臭氧气体辅助治疗COVID-19感染所致肺部呼吸系统疾病:一项前瞻性随机试验
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-01 DOI: 10.4103/2045-9912.326001
Erhan Dengiz, Çağrı Özcan, Yusuf İzzettin Güven, Selcen Uçar, Behçet Kemal Ener, Semih Sözen, Buket Yağcı, İnal Albek Güzel, Betül Yiğit, Aslınur Andaç, Beyza Güneş, Emire Bor, Uğur Karabudak, Ali Kaya

The objective of this study was to provide lung disinfection by nebulizing ozone gas with distilled water and olive oil for patients who have clinical symptoms due to coronavirus disease 2019 (COVID-19). The study attempted to reduce the viral load of COVID-19 in the lungs of patients, to provide a faster response to medical treatment. Between August 2020 and September 2020, 30 patients who met the study criteria were prospectively evaluated. There were 2 groups with 15 patients in each group: patients in control group were not treated with ozone and only received standard COVID-19 treatment; patients in ozone group received lung disinfection technique with ozone and standard COVID-19 treatment. A statistically significant difference was found in the length of stay in hospital, change in C-reactive protein, polymerase chain reaction results after 5 days, and computed tomography scores between two groups. There was no statistically significant difference in D-dimer, urea, lactate dehydrogenase, lymphocyte, leukocyte, and platelet between two groups. According to the data, we think that the lung disinfection technique applied with ozone inhalation reduces the rate of pneumonia in COVID-19 patients and makes the patients respond faster to the treatment and become negative according to the polymerase chain reaction tests. The study was approved by the Ethical Committee of the Istanbul Medipol University Clinical Trials (approval No. 0011) on July 2, 2020.

本研究的目的是用蒸馏水和橄榄油雾化臭氧气体,为有临床症状的2019冠状病毒病(COVID-19)患者提供肺部消毒。该研究试图减少患者肺部COVID-19的病毒载量,以便对医疗做出更快的反应。在2020年8月至2020年9月期间,对30名符合研究标准的患者进行了前瞻性评估。分为2组,每组15例:对照组患者不进行臭氧治疗,仅接受标准的COVID-19治疗;臭氧组患者采用臭氧肺消毒技术和新冠肺炎标准治疗。两组患者住院时间、c反应蛋白变化、5 d后聚合酶链反应结果、ct评分差异均有统计学意义。两组患者d -二聚体、尿素、乳酸脱氢酶、淋巴细胞、白细胞、血小板等指标比较,差异均无统计学意义。根据数据,我们认为采用臭氧吸入肺部消毒技术降低了COVID-19患者肺炎的发病率,使患者对治疗反应更快,聚合酶链反应试验呈阴性。该研究于2020年7月2日获得伊斯坦布尔Medipol大学临床试验伦理委员会(批准号0011)的批准。
{"title":"Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial.","authors":"Erhan Dengiz,&nbsp;Çağrı Özcan,&nbsp;Yusuf İzzettin Güven,&nbsp;Selcen Uçar,&nbsp;Behçet Kemal Ener,&nbsp;Semih Sözen,&nbsp;Buket Yağcı,&nbsp;İnal Albek Güzel,&nbsp;Betül Yiğit,&nbsp;Aslınur Andaç,&nbsp;Beyza Güneş,&nbsp;Emire Bor,&nbsp;Uğur Karabudak,&nbsp;Ali Kaya","doi":"10.4103/2045-9912.326001","DOIUrl":"https://doi.org/10.4103/2045-9912.326001","url":null,"abstract":"<p><p>The objective of this study was to provide lung disinfection by nebulizing ozone gas with distilled water and olive oil for patients who have clinical symptoms due to coronavirus disease 2019 (COVID-19). The study attempted to reduce the viral load of COVID-19 in the lungs of patients, to provide a faster response to medical treatment. Between August 2020 and September 2020, 30 patients who met the study criteria were prospectively evaluated. There were 2 groups with 15 patients in each group: patients in control group were not treated with ozone and only received standard COVID-19 treatment; patients in ozone group received lung disinfection technique with ozone and standard COVID-19 treatment. A statistically significant difference was found in the length of stay in hospital, change in C-reactive protein, polymerase chain reaction results after 5 days, and computed tomography scores between two groups. There was no statistically significant difference in D-dimer, urea, lactate dehydrogenase, lymphocyte, leukocyte, and platelet between two groups. According to the data, we think that the lung disinfection technique applied with ozone inhalation reduces the rate of pneumonia in COVID-19 patients and makes the patients respond faster to the treatment and become negative according to the polymerase chain reaction tests. The study was approved by the Ethical Committee of the Istanbul Medipol University Clinical Trials (approval No. 0011) on July 2, 2020.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 2","pages":"55-59"},"PeriodicalIF":2.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/51/MGR-12-55.PMC8562398.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39542731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report. SARS-CoV-2疫苗(科兴®)后急性哮喘加重1例报告
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-01 DOI: 10.4103/2045-9912.326003
Fatih Uzer, Aykut Cilli

A 76-year-old female received a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac, Sinovac®, Beijing, China) and subsequently experienced chest discomfort. A computed tomography performed 1 day after vaccination showed multiple infiltrations in both lungs and ground-glass shadows in both lung fields. Her fingertip oxygen saturation was 81% and there was widespread wheezing on physical examination. Based on these findings, the patient was hospitalized with a preliminary diagnosis of drug-induced pneumonitis and acute asthma exacerbation due to a SARS-CoV-2 vaccine. During her hospitalization, 40 mg/d systemic steroid, 4 times a day salbutamol nebulized, 2 L/min inhaled oxygen therapy and 400 mg/d moxifloxacin intravenous were administered for 5 days. One month later, the thorax computed tomography scan revealed that the previous findings were almost completely regressed.

一名76岁女性接种了严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)疫苗(CoronaVac, Sinovac®,北京,中国),随后出现胸部不适。接种疫苗1天后进行的计算机断层扫描显示双肺多发浸润,双肺野可见磨玻璃影。她的指尖氧饱和度为81%,体格检查有广泛的喘息。根据这些发现,患者住院治疗,初步诊断为SARS-CoV-2疫苗引起的药物性肺炎和急性哮喘加重。住院期间给予全身类固醇40 mg/d,沙丁胺醇雾化4次/d,吸氧2 L/min,莫西沙星静脉注射400 mg/d,连续5天。一个月后,胸部计算机断层扫描显示先前的发现几乎完全恢复。
{"title":"Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report.","authors":"Fatih Uzer,&nbsp;Aykut Cilli","doi":"10.4103/2045-9912.326003","DOIUrl":"https://doi.org/10.4103/2045-9912.326003","url":null,"abstract":"<p><p>A 76-year-old female received a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac, Sinovac<sup>®</sup>, Beijing, China) and subsequently experienced chest discomfort. A computed tomography performed 1 day after vaccination showed multiple infiltrations in both lungs and ground-glass shadows in both lung fields. Her fingertip oxygen saturation was 81% and there was widespread wheezing on physical examination. Based on these findings, the patient was hospitalized with a preliminary diagnosis of drug-induced pneumonitis and acute asthma exacerbation due to a SARS-CoV-2 vaccine. During her hospitalization, 40 mg/d systemic steroid, 4 times a day salbutamol nebulized, 2 L/min inhaled oxygen therapy and 400 mg/d moxifloxacin intravenous were administered for 5 days. One month later, the thorax computed tomography scan revealed that the previous findings were almost completely regressed.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 2","pages":"67-68"},"PeriodicalIF":2.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/f1/MGR-12-67.PMC8562397.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39542733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
COVID-19 is more dangerous for older people and its severity is increasing: a case-control study. 一项病例对照研究表明,COVID-19对老年人更危险,其严重程度正在增加。
IF 2.9 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2022-04-01 DOI: 10.4103/2045-9912.325992
Cuma Mertoglu, Mehmet Tahir Huyut, Hasan Olmez, Mustafa Tosun, Mecit Kantarci, Taha Abdulkadir Coban

Coronavirus disease 2019 (COVID-19) triggers important changes in routine blood tests. In this retrospective case-control study, biochemical, hematological and inflammatory biomarkers between March 10, 2020, and November 30, 2020 from 3969 COVID-19 patients (3746 in the non-intensive care unit (non-ICU) group and 223 in the ICU group) were analyzed by dividing into three groups as spring, summer and autumn. In the non-ICU group, lymphocyte to monocyte ratio was lower in autumn than the other two seasons and neutrophil to lymphocyte ratio was higher in autumn than the other two seasons. Also, monocyte and platelet were higher in spring than autumn; and eosinophil, hematocrit, hemoglobin, lymphocyte, and red blood cells decreased from spring to autumn. In the non-ICU group, alanine aminotransferase and gamma-glutamyltransferase gradually increased from spring to autumn, while albumin, alkaline phosphatase, calcium, total bilirubin and total protein gradually decreased. Additionally, C-reactive protein was higher in autumn than the other seasons, erythrocyte sedimentation rate was higher in autumn than summer. The changes in routine blood biomarkers in COVID-19 varied from the emergence of the disease until now. Also, the timely changes of blood biomarkers were mostly more negative, indicating that the disease progresses severely. The study was approved by the Erzincan Binali Yildirim University Non-interventional Clinical Trials Ethic Committee (approval No. 86041) on June 21, 2021.

2019冠状病毒病(新冠肺炎)引发血液常规检测的重要变化。在这项回顾性病例对照研究中,分析了2020年3月10日至2020年11月30日期间3969名新冠肺炎患者(非重症监护室(非ICU)组3746人,ICU组223人)的生化、血液学和炎症生物标志物,分为春季、夏季和秋季三组。在非ICU组中,秋季淋巴细胞与单核细胞的比率低于其他两个季节,秋季中性粒细胞与淋巴细胞的比率高于其他两个季度。单核细胞和血小板在春季高于秋季;从春季到秋季,嗜酸性粒细胞、红细胞压积、血红蛋白、淋巴细胞和红细胞减少。在非ICU组,丙氨酸氨基转移酶和γ-谷氨酰转移酶从春季到秋季逐渐升高,而白蛋白、碱性磷酸酶、钙、总胆红素和总蛋白逐渐降低。此外,C反应蛋白在秋季高于其他季节,红细胞沉降率在秋季高于夏季。从疾病出现到现在,新冠肺炎常规血液生物标志物的变化各不相同。此外,血液生物标志物的及时变化大多为阴性,表明疾病进展严重。该研究于2021年6月21日获得Erzincan Binali Yildirim大学非介入临床试验伦理委员会的批准(批准号86041)。
{"title":"COVID-19 is more dangerous for older people and its severity is increasing: a case-control study.","authors":"Cuma Mertoglu,&nbsp;Mehmet Tahir Huyut,&nbsp;Hasan Olmez,&nbsp;Mustafa Tosun,&nbsp;Mecit Kantarci,&nbsp;Taha Abdulkadir Coban","doi":"10.4103/2045-9912.325992","DOIUrl":"10.4103/2045-9912.325992","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) triggers important changes in routine blood tests. In this retrospective case-control study, biochemical, hematological and inflammatory biomarkers between March 10, 2020, and November 30, 2020 from 3969 COVID-19 patients (3746 in the non-intensive care unit (non-ICU) group and 223 in the ICU group) were analyzed by dividing into three groups as spring, summer and autumn. In the non-ICU group, lymphocyte to monocyte ratio was lower in autumn than the other two seasons and neutrophil to lymphocyte ratio was higher in autumn than the other two seasons. Also, monocyte and platelet were higher in spring than autumn; and eosinophil, hematocrit, hemoglobin, lymphocyte, and red blood cells decreased from spring to autumn. In the non-ICU group, alanine aminotransferase and gamma-glutamyltransferase gradually increased from spring to autumn, while albumin, alkaline phosphatase, calcium, total bilirubin and total protein gradually decreased. Additionally, C-reactive protein was higher in autumn than the other seasons, erythrocyte sedimentation rate was higher in autumn than summer. The changes in routine blood biomarkers in COVID-19 varied from the emergence of the disease until now. Also, the timely changes of blood biomarkers were mostly more negative, indicating that the disease progresses severely. The study was approved by the Erzincan Binali Yildirim University Non-interventional Clinical Trials Ethic Committee (approval No. 86041) on June 21, 2021.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"12 2","pages":"51-54"},"PeriodicalIF":2.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/d1/MGR-12-51.PMC8562399.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
期刊
Medical Gas Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1